Evidence map›Paper›PMID 38861293›Full record

ArticleFuture oncology (London, England)2024

COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.

Nilofer Azad, Zishuo Hu, Ilyas Sahin, Renuka Iyer, Olivia Aranha, Howard Hochster, Priyadarshini Pathak, Andrew Scott Paulson, Aparna Kalyan, Chih-Yi Liao and 15 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Nilofer AzadSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA.
Zishuo HuDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ilyas SahinDepartment of Medicine University of Florida Health Cancer Center, Gainesville, FL 32610, USA.
Renuka IyerDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Olivia AranhaSiteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA.
Howard HochsterGastrointestinal Oncology, Rutgers Cancer Institute New Jersey, New Brunswick, NJ 08903, USA.
Priyadarshini PathakDepartment of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Andrew Scott PaulsonTexas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX 75246, USA.
Aparna KalyanRobert H. Lurie Comprehensive Cancer, Division of Hematology & Oncology, Northwestern University, Chicago, IL 60611, USA.
Chih-Yi LiaoSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Nguyen TranDepartment of Oncology, Division of Medical Oncology, Mayo Clinic Rochester, MN 55905, USA.
Robin K KelleyDivision of Hematology/Oncology, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA.
Gregory HeestandDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
David CosgroveSarah Cannon Research Institute, Compass Oncology, Vancouver, WA 98684, USA.
Anthony El-KhoueiryUSC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Mitesh BoradDepartment of Hematology-Oncology, Mayo Clinic Cancer Center, Phoenix, AZ 85054, USA.
Nashat Y GabrailGabrail Cancer Center Research, Canton, OH 44718, USA.
Umair MajeedDivision of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Lingling DuOchsner MD Anderson Cancer Center, Ochsner Health, New Orleans, LA 70115, USA.
Suneel KamathDepartment of Hematology Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44106, USA.
Nathan ShumwayTexas Oncology, San Antonio, TX 78258, USA.
Rachna ShroffDivision of Hematology and Oncology, Department of Medicine, University of Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA.
Lipika GoyalDepartment of Medicine, Division of Hematology and Oncology, Stanford Cancer Center, Palo Alto, CA 94305, USA.
Minori RosalesCompass Therapeutics, 80 Guest Street, Boston, MA 02135, USA.
Milind JavleDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Funding

Working to Eliminate Care Disparities in Liver Cancer in Southeast Asian Americans: Transportation and Other Social Determinants of Health.K23MD017217 · NIMHD · MAYO CLINIC ROCHESTER · PI Nguyen H Tran · 2022 to 2026
$818k
NIMHD NIH HHS K23 MD017217
6 · The paper itself

Abstract

Treatment options for patients with biliary tract cancer are limited, and the prognosis is poor. CTX-009, a novel bispecific antibody targeting both DLL4 and VEGF-A, has demonstrated antitumor activity in patients with advanced cancers as both a monotherapy and in combination with chemotherapy. In a phase II study of patients with advanced biliary tract cancer who had received one or two prior therapies, CTX-009 with paclitaxel demonstrated a 37.5% overall response rate (ORR). Described here is the design of and rationale for COMPANION-002, a randomized phase II/III study, which will evaluate the safety and efficacy of CTX-009 in combination with paclitaxel versus paclitaxel alone as second-line treatment for patients with advanced biliary tract cancer. The primary end point is ORR, and crossover is allowed.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiliary Tract NeoplasmsPaclitaxelAdultAgedAntibodies, BispecificClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFemaleHumansMaleMiddle AgedRandomized Controlled Trials as TopicTreatment OutcomeVascular Endothelial Growth Factor AAntibodies, BispecificPaclitaxelVascular Endothelial Growth Factor Aanti-angiogenesisbiliary tract cancercholangiocarcinomaclinical trialCTX-009DLL4PaclitaxelVEGF

Identifiers

PMID38861293
PMCPMC11509068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.